maripoc-banner-picture-with-kids-smiling
Home | News | Study: Diagnosis of respiratory tract infections caused by human bocavirus 1
25.10.2022

Press release: New scientific reports demonstrate the high accuracy of mariPOC COVID-19 tests in decentralized testing

21.6.2022

Nasal sampling and EU RAT list

20.7.2021

mariPOC COVID-19 tests are suitable for travel certificates in the EU

4.3.2021

Press release: ArcDia launches a quick and automated COVID-19 antigen test with superior performance

10.9.2020

Press release: Bruker to distribute ArcDia’s mariPOC® products for automated antigen POCT of COVID-19 and other infectious diseases in Central Europe

25.5.2020

Press release: ArcDia Ltd’s automated coronavirus point-of-care test CE marked and available

27.4.2020

Press Release: ArcDia Ltd reports a breakthrough in the development of an automated coronavirus point-of-care test

26.3.2020

Press Release: ArcDia’s products would allow testing of all respiratory tract and COVID-19 patients in Finland

11.3.2020

Press Release: ArcDia International Ltd develops a COVID-19 test for primary care

14.10.2019

Pathogen Detection in Perianal Streptococcal Dermatitis

7.10.2019

Mr. Vesa Kemppainen appointed as the new CEO

30.9.2019

New mariPOC® publication: Evaluation of a Gastrointestinal Pathogen Panel Immunoassay in Stool Testing of Patients with Suspected Clostridioides (Clostridium) difficile Infection.

30.9.2019

New mariPOC® publication: Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children.

9.4.2019

ArcDia has entered into an exclusive license agreement with Xinhua Healthcare for the commercialisation of ArcDia’s mariPOC® technology in China

24.5.2018

mariPOC® ensures lower probability for C. difficile misdiagnosis with precision

8.2.2018

New research data shows that influenza antigen testing correlates best with the infectivity period

1.11.2017

Press release: New test for detection of C. difficile infection

2.8.2017

New QuickStrepA

6.4.2017

Study: Diagnosis of respiratory tract infections caused by human bocavirus 1

7.3.2017

New mariPOC influenza A virus test with significantly improved sensitivity

21.12.2016

New test for Flu A

8.6.2016

World’s fastest antibiotic resistance testing

28.4.2016

New mariPOC® Gastro test available

17.3.2016

Detection and monitoring of human bocavirus 1 infection by a new rapid antigen test

2.2.2016

ArcDia contributes solving the global problem of antimicrobial resistance

9.12.2015

Press release: Spanish clinical study demonstrates mariPOC’s excellent performance

1.9.2015

ArcDia is developing pandemics preparedness

11.5.2015

The diagnostics of group A streptococcus from pharyngeal swab samples by bacterial culture is challenged by a novel mariPOC point of care test.

31.10.2014

The Flu Season Has Begun – mariPOC® Helps

9.10.2014

Nobel Prize awarded to mariPOC® sister technology

3.10.2014

The Evolution of Rapid POC Tests for Infectious Disease Diagnostics: An Exclusive SelectScience Interview

9.4.2014

ArcDia Receives Frost & Sullivan Award for Point-of-Care Product Leadership!

24.1.2014

ArcDia launches world’s first antigen test for human bocavirus – Press Release

24.9.2013

New press release

6.4.2017

Study: Diagnosis of respiratory tract infections caused by human bocavirus 1

Human bocavirus 1 (HBoV1) causes respiratory tract infections in infants and children. Diagnosis of acute HBoV1 infections is challenging as viral DNA is frequently detected in asymptomatic controls and as co-finding with other viruses. Recently developed novel HBoV1 mRNA and antigen tests may improve the diagnosis of acute HBoV1 infections.

Read the entire article here.